Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
24.91
-0.39 (-1.54%)
At close: Mar 28, 2025, 4:00 PM
24.43
-0.48 (-1.93%)
After-hours: Mar 28, 2025, 4:54 PM EDT
Pacira BioSciences Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Pacira BioSciences stock have an average target of 30.67, with a low estimate of 10 and a high estimate of 70. The average target predicts an increase of 23.12% from the current stock price of 24.91.
Analyst Consensus: Buy
* Price targets were last updated on Feb 28, 2025.
Analyst Ratings
The average analyst rating for Pacira BioSciences stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 3 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Total | 11 | 10 | 10 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $17 → $24 | Buy | Maintains | $17 → $24 | -3.65% | Feb 28, 2025 |
| Needham | Needham | Strong Buy Maintains $30 → $32 | Strong Buy | Maintains | $30 → $32 | +28.46% | Feb 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $57 → $70 | Strong Buy | Maintains | $57 → $70 | +181.01% | Feb 28, 2025 |
| Truist Securities | Truist Securities | Strong Sell → Hold Upgrades $8 → $25 | Strong Sell → Hold | Upgrades | $8 → $25 | +0.36% | Jan 30, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $18 | Hold | Reiterates | $18 | -27.74% | Jan 14, 2025 |
Financial Forecast
Revenue This Year
769.45M
from 700.97M
Increased by 9.77%
Revenue Next Year
845.12M
from 769.45M
Increased by 9.83%
EPS This Year
3.51
from -2.15
EPS Next Year
4.24
from 3.51
Increased by 20.78%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 833.9M | 966.5M | 1.1B | ||
| Avg | 769.5M | 845.1M | 932.8M | ||
| Low | 715.5M | 738.4M | 798.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.0% | 25.6% | 30.5% | ||
| Avg | 9.8% | 9.8% | 10.4% | ||
| Low | 2.1% | -4.0% | -5.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.43 | 6.10 | 6.46 | ||
| Avg | 3.51 | 4.24 | 4.18 | ||
| Low | 2.58 | 3.26 | 3.02 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 73.7% | 52.2% | ||
| Avg | - | 20.8% | -1.4% | ||
| Low | - | -7.1% | -28.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.